Souhaitez-vous accéder aux communiqués récents ?

An NTHU cancer study reveals how glutathione (GSH) supports cancer cell metabolism and identifies a dual-targeting strategy to induce ferroptosis.

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing...

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential first-in-class ATR Inhibitor, alnodesertib  Following encouraging ESMO...

Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse Adcytherix reinforces its Executive Committee with two pivotal appointments: CMO and CFOThe ADCX...

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical...

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were...

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage...

NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.